- Home
- DUKR vs AKTX Comparison
DUKR vs AKTX Comparison
Compare DUKR & AKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DUKR | AKTX |
|---|---|---|
| Founded | N/A | N/A |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.1M | 18.2M |
| IPO Year | 2015 | 2014 |
Fundamental Metrics
Financial Performance| Metric | DUKR | AKTX |
|---|---|---|
| Price | $5.31 | $7.72 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $33.50 |
| AVG Volume (30 Days) | 12.5K | ★ 28.4K |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $377,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 249.07 | N/A |
| 52 Week Low | $4.75 | $0.12 |
| 52 Week High | $7.41 | $29.32 |
Technical Indicators
Market Signals| Indicator | DUKR | AKTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.51 | 41.06 |
| Support Level | $4.86 | $0.21 |
| Resistance Level | $5.90 | $15.50 |
| Average True Range (ATR) | 0.45 | 0.67 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 49.07 | 44.00 |
Price Performance
Historical ComparisonAbout AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.